Industry Economy TECH GAME
Society Comfort AUTO MEDIA

John Rim, CEO of Samsung Biologics shares future plans at BIO Digital 2021

  • Wednesday, June 16, 2021, 10:03 am
  • ACROFAN=Newswire
Samsung Biologics' CEO, John Rim, delivered the opening remarks at BIO Digital 2021 in an exclusive keynote session with Richard N. Hass, President of the Council on Foreign Relations on Tuesday, June 15th. In his speech, Rim highlighted the industry’s continuing efforts and contribution in the battle against COVID-19 and also shared the company’s vision and long-term plans to better serve existing and potential clients.

“As most recently announced, we are fully committed to leveraging our experience in manufacturing technologies to support the aseptic fill and finish of Moderna’s mRNA-1273 vaccine with quality, speed, and efficiency to aid in the fight against this global crisis,” Rim said. “We will be also adding a dedicated production suite for mRNA bulk drug substance to our existing facility by the first half of 2022, which will enable us to rapidly manufacture and supply future vaccines and treatments against multiple targets.”

Joon Chang, Senior Director of Global Sales and Operations Center will be presenting during a fireside chat on June 16th at 3PM (EDT) on the emerging trends of CDMO industry and its partnership highlighting the unique values that Samsung Biologics delivers to clients.

Also this week, Sam MacHour, Senior Vice President & Chief Quality Officer, joined Dan Stanton of BioProcess International in an on demand interview, where he discussed how both Samsung Biologics and the CDMO sector have rapidly responded to biopharma's COVID-19 challenges, and talked about how Samsung Biologics has emerged as one of the largest CDMOs in just a decade, as well as its future plans for the CDMO space and beyond.

In response to an increasing worldwide demand for biopharmaceuticals, Samsung Biologics has been taking preemptive approaches to actively accommodate the evolving needs of the industry through continuous innovation and investments including the addition of its fourth and largest plant, San Francisco R&D Center, and mRNA vaccine drug substance manufacturing and filling capabilities.

Visit here to join us at BIO Digital 2021 and find the right solution with us for your success.